STRUCTURE-FUNCTION ANALYSIS OF ABCA4 MEMBRANE TRANSPORTER: DEVELOPMENT OF A SOLUBLE MODEL SYSTEM
Date
2024-02-29
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of Delaware
Abstract
The fourth member of ABCA subfamily transporter protein, ABCA4, is highly expressed and localized in the rod and cone outer segment discs of photoreceptor cells. It plays a pivotal role in the visual cycle by translocating its physiological substrates (retinoid by-products such as N-retinylidene-phosphatidylethanolamine (N-Ret-PE)) across the disc membrane for further recycling in the retinal pigment epithelium (RPE). Dysfunctions and mutations in the ABCA4 gene lead to various inherited visual diseases such as Stargardt disease (STGD1), cone-rod dystrophy, retinitis pigmentosa, and fundus flavimicalatus. Over 3,000 variants have been identified and linked to the ABCA4 gene. Still, half of these reported variants lack information as to what extent they can affect the molecular/biochemical properties of ABCA4. The large size and the nature of the twelve transmembrane domains (12-TMα-H) of ABCA4 are significant reasons for the slow progress in characterizing ABCA4 genetic variants in vitro.
In this dissertation, I tested the hypothesis of creating a soluble analog of the ABCA4, which would facilitate the study of this integral transporter protein. We aim to obtain the soluble form of ABCA4 from the cytoplasmic extract without the need to reconstitute it into liposomes but retain the overall structure and function of the protein. The foundation of our membrane solubilization approach was based on the QTY code, which utilizes the substitution of hydrophobic amino acids (leucine, isoleucine, valine, and phenylalanine (LIVF)) in membrane-spanning helices with hydrophilic amino acids (glutamine, threonine, and tyrosine (QTY)) possessing electron density map. Our results indicated that modifications of QTY were necessary. These included (i) narrowing down the selected hydrophobic residue (LIVF) from substitutions to exclusively the lipid- exposed residues in the 12-TMα-H, (ii) eliminating clinically reported pathogenic variants from the QTY substitution, and (iii) employing the Asn amino acid with the Gln to substitute the Leu residue based on bioinformatics pathogenicity prediction software. The modified approach, which resulted in a solubilized transporter (ABCA4S), was designated as the QNTY approach to reflect the incorporation of Asn in the approach. Using this approach, I have developed a novel system for efficient expression, solubilization, and characterization of the ABCAS and its disease-associated variants in the baculovirus expression system. Our key findings from designing the soluble construct, ABCA4S, indicate that eliminating deleterious mutation from the QTY substitution played a significant role in preventing the lack of expression of the protein. ABCA4S protein was successfully expressed in high yield utilizing a baculovirus expression system and attained from the cytosolic extract.
Structural and functional analysis of ABCA4S were compared to the native ABCA4N. Computational analysis using molecular modeling AlphaFold-2 compared the structures of the soluble ABCA4S and the native ABCA4N. The superimposition of the structures showed a close alignment and low RMSD values. Functional analysis of retinal stimulated ATPase demonstrated that ABCA4S exhibited comparable activity as the native ABCA4N. We have utilized the platform to analyze selected disease-associated variants and found their effects on retinal stimulated ATPase were comparable to that previously reported in the literature. These results suggest that QNTY presented here can be applied to other large transporter proteins and may aid in the functional assessment of clinically relevant genetic variants and protein function.
Description
Keywords
ABCA4, Transporter Protein, Protein Solubilization
Citation
1. Higgins, C.F., ABC transporters: from microorganisms to man. Annu Rev Cell Biol, 1992. 8: p. 67-113. 2. Hediger, M.A., et al., The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med, 2013. 34(2-3): p. 95-107. 3. Higgins, C.F., et al., A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature, 1986. 323(6087): p. 448-50. 4. Biswas-Fiss, E.E., et al., ABCA Transporters, in Encyclopedia of Signaling Molecules, S. Choi, Editor. 2018, Springer International Publishing: Cham. p. 54- 68. 5. Jones, P.M. and A.M. George, The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci, 2004. 61(6): p. 682-99. 6. Liu, X., ABC Family Transporters. Adv Exp Med Biol, 2019. 1141: p. 13-100. 7. Dean, M., Y. Hamon, and G. Chimini, The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 2001. 42(7): p. 1007-17. 8. Higgins, C.F., ABC transporters: physiology, structure and mechanism--an overview. Res Microbiol, 2001. 152(3-4): p. 205-10. 9. Broccardo, C., M. Luciani, and G. Chimini, The ABCA subclass of mammalian transporters. Biochim Biophys Acta, 1999. 1461(2): p. 395-404. 10. Kaminski, W.E., A. Piehler, and J.J. Wenzel, ABC A-subfamily transporters: structure, function and disease. Biochim Biophys Acta, 2006. 1762(5): p. 510-24. 11. Albrecht, C. and E. Viturro, The ABCA subfamily--gene and protein structures, functions and associated hereditary diseases. Pflugers Arch, 2007. 453(5): p. 581- 9. 12. Piehler, A.P., et al., [ABCA-transporters: regulators of cellular lipid transport]. Tidsskr Nor Laegeforen, 2007. 127(22): p. 2930-3. 13. Schmitz, G. and W.E. Kaminski, ABCA2: a candidate regulator of neural transmembrane lipid transport. Cell Mol Life Sci, 2002. 59(8): p. 1285-95. 14. Chen, L., et al., Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle, 2022. 21(11): p. 1121-1139. 15. Beers, M.F. and S. Mulugeta, The biology of the ABCA3 lipid transporter in lung health and disease. Cell Tissue Res, 2017. 367(3): p. 481-493. 16. Kim, M.S., S.H. Yang, and M.S. Kim, Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells. Biochem Biophys Res Commun, 2023. 666: p. 1-9. 121 17. Davis, W., Jr. and K.D. Tew, ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target. Biochem Pharmacol, 2018. 151: p. 188-200. 18. Steinbach, D., et al., ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res, 2006. 12(14 Pt 1): p. 4357-63. 19. Chapuy, B., et al., Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia, 2008. 22(8): p. 1576-86. 20. Sun, H., R.S. Molday, and J. Nathans, Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. J Biol Chem, 1999. 274(12): p. 8269-81. 21. Beharry, S., M. Zhong, and R.S. Molday, N-retinylidene- phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4 (ABCR). J Biol Chem, 2004. 279(52): p. 53972-9. 22. Landrum, M.J., et al., ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res, 2014. 42(Database issue): p. D980-5. 23. Landrum, M.J., et al., ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 2018. 46(D1): p. D1062-d1067. 24. Cevik, S., S.B. Biswas, and E.E. Biswas-Fiss, Structural and Pathogenic Impacts of ABCA4 Variants in Retinal Degenerations-An In-Silico Study. Int J Mol Sci, 2023. 24(8). 25. Cremers, F.P.M., et al., Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. Prog Retin Eye Res, 2020. 79: p. 100861. 26. Al-Khuzaei, S., et al., An Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story. Genes (Basel), 2021. 12(8). 27. Qian, X.H., et al., ABCA7-Associated Clinical Features and Molecular Mechanisms in Alzheimer's Disease. Mol Neurobiol, 2023. 60(10): p. 5548-5556. 28. Fu, Y., et al., ABCA5 regulates amyloid-β peptide production and is associated with Alzheimer's disease neuropathology. J Alzheimers Dis, 2015. 43(3): p. 857- 69. 29. Bossaerts, L., R. Cacace, and C. Van Broeckhoven, The role of ATP-binding cassette subfamily A in the etiology of Alzheimer's disease. Mol Neurodegener, 2022. 17(1): p. 31. 30. Choi, H.Y., et al., Biomedical Advances in ABCA1 Transporter: From Bench to Bedside. Biomedicines, 2023. 11(2). 31. Mack, J.T., C.B. Brown, and K.D. Tew, ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opin Ther Targets, 2008. 12(4): p. 491-504. 32. Hedditch, E.L., et al., ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst, 2014. 106(7). 33. Imperio, G.E., et al., Gestational age-dependent gene expression profiling of ATP-binding cassette transporters in the healthy human placenta. J Cell Mol 122 Med, 2019. 23(1): p. 610-618. 34. Cui, Y., et al., ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res, 2020. 39(1): p. 90. 35. Hwang, H.J., K.H. Lee, and J.Y. Cho, ABCA9, an ER cholesterol transporter, inhibits breast cancer cell proliferation via SREBP-2 signaling. Cancer Sci, 2023. 114(4): p. 1451-1463. 36. Papermaster, D.S., et al., Immunocytochemical localization of a large intrinsic membrane protein to the incisures and margins of frog rod outer segment disks. J Cell Biol, 1978. 78(2): p. 415-25. 37. Braekevelt, C.R., Retinal photoreceptor fine structure in the red-tailed hawk (Buteo jamaicensis). Anat Histol Embryol, 1993. 22(3): p. 222-32. 38. Molday, R.S. and L.L. Molday, Identification and characterization of multiple forms of rhodopsin and minor proteins in frog and bovine rod outer segment disc membranes. Electrophoresis, lectin labeling, and proteolysis studies. J Biol Chem, 1979. 254(11): p. 4653-60. 39. Papermaster, D.S., P. Reilly, and B.G. Schneider, Cone lamellae and red and green rod outer segment disks contain a large intrinsic membrane protein on their margins: an ultrastructural immunocytochemical study of frog retinas. Vision Res, 1982. 22(12): p. 1417-28. 40. Illing, M., L.L. Molday, and R.S. Molday, The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. J Biol Chem, 1997. 272(15): p. 10303-10. 41. Azarian, S.M. and G.H. Travis, The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). FEBS Lett, 1997. 409(2): p. 247-52. 42. Allikmets, R., et al., A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet, 1997. 15(3): p. 236-46. 43. Nasonkin, I., et al., Mapping of the rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1 and identification of novel mutations in Stargardt's disease. Hum Genet, 1998. 102(1): p. 21-6. 44. Weng, J., et al., Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell, 1999. 98(1): p. 13-23. 45. Molday, R.S., et al., Structure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration. Prog Retin Eye Res, 2022. 89: p. 101036. 46. Tsybovsky, Y., R.S. Molday, and K. Palczewski, The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol, 2010. 703: p. 105-25. 47. Tsybovsky, Y. and K. Palczewski, Expression, purification and structural properties of ABC transporter ABCA4 and its individual domains. Protein Expr Purif, 2014. 97: p. 50-60. 123 48. Liu, F., J. Lee, and J. Chen, Molecular structures of the eukaryotic retinal importer ABCA4. Elife, 2021. 10. 49. Scortecci, J.F., et al., Cryo-EM structures of the ABCA4 importer reveal mechanisms underlying substrate binding and Stargardt disease. Nat Commun, 2021. 12(1): p. 5902. 50. Xie, T., et al., Structural basis of substrate recognition and translocation by human ABCA4. Nat Commun, 2021. 12(1): p. 3853. 51. Qian, H., et al., Structure of the Human Lipid Exporter ABCA1. Cell, 2017. 169(7): p. 1228-1239.e10. 52. Ahn, J., J.T. Wong, and R.S. Molday, The effect of lipid environment and retinoids on the ATPase activity of ABCR, the photoreceptor ABC transporter responsible for Stargardt macular dystrophy. J Biol Chem, 2000. 275(27): p. 20399-405. 53. Biswas-Fiss, E.E., et al., Interaction of extracellular domain 2 of the human retina-specific ATP-binding cassette transporter (ABCA4) with all-trans-retinal. J Biol Chem, 2010. 285(25): p. 19372-83. 54. Fokkema, I.F., J.T. den Dunnen, and P.E. Taschner, LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat, 2005. 26(2): p. 63-8. 55. Allikmets, R., et al., Mutation of the Stargardt disease gene (ABCR) in age- related macular degeneration. Science, 1997. 277(5333): p. 1805-7. 56. Xiao, X., et al., Clinical Observation and Genotype-Phenotype Analysis of ABCA4- Related Hereditary Retinal Degeneration before Gene Therapy. Curr Gene Ther, 2022. 22(4): p. 342-351. 57. Khan, M. and F.P.M. Cremers, ABCA4-Associated Stargardt Disease. Klin Monbl Augenheilkd, 2020. 237(3): p. 267-274. 58. Stenson, P.D., et al., Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat, 2003. 21(6): p. 577-81. 59. Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 7(4): p. 248-9. 60. Ioannidis, N.M., et al., REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet, 2016. 99(4): p. 877- 885. 61. Pejaver, V., et al., Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. Nat Commun, 2020. 11(1): p. 5918. 62. Rentzsch, P., et al., CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res, 2019. 47(D1): p. D886-d894. 63. Mirdita, M., et al., ColabFold: making protein folding accessible to all. Nat Methods, 2022. 19(6): p. 679-682. 64. Smorodina, E., et al., Structural informatic study of determined and AlphaFold2 predicted molecular structures of 13 human solute carrier transporters and their water-soluble QTY variants. Sci Rep, 2022. 12(1): p. 20103. 65. Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.8. 2015. 66. Garces, F., et al., Correlating the Expression and Functional Activity of ABCA4 124 Disease Variants With the Phenotype of Patients With Stargardt Disease. Invest Ophthalmol Vis Sci, 2018. 59(6): p. 2305-2315. 67. Ahn, J., et al., Functional interaction between the two halves of the photoreceptor-specific ATP binding cassette protein ABCR (ABCA4). Evidence for a non-exchangeable ADP in the first nucleotide binding domain. J Biol Chem, 2003. 278(41): p. 39600-8. 68. Zhong, M., L.L. Molday, and R.S. Molday, Role of the C terminus of the photoreceptor ABCA4 transporter in protein folding, function, and retinal degenerative diseases. J Biol Chem, 2009. 284(6): p. 3640-9. 69. Garces, F.A., J.F. Scortecci, and R.S. Molday, Functional Characterization of ABCA4 Missense Variants Linked to Stargardt Macular Degeneration. Int J Mol Sci, 2020. 22(1). 70. Ścieżyńska, A., et al., Molecular Analysis of the ABCA4 Gene Mutations in Patients with Stargardt Disease Using Human Hair Follicles. Int J Mol Sci, 2020. 21(10). 71. Pollock, N.L., et al., Improving the stability and function of purified ABCB1 and ABCA4: the influence of membrane lipids. Biochim Biophys Acta, 2014. 1838(1 Pt B): p. 134-47. 72. Jamieson, S.E., et al., Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One, 2008. 3(6): p. e2285. 73. Aukrust, I., et al., The intronic ABCA4 c.5461-10T>C variant, frequently seen in patients with Stargardt disease, causes splice defects and reduced ABCA4 protein level. Acta Ophthalmol, 2017. 95(3): p. 240-246. 74. Biswas, E.E., Nucleotide binding domain 1 of the human retinal ABC transporter functions as a general ribonucleotidase. Biochemistry, 2001. 40(28): p. 8181-7. 75. Biswas-Fiss, E.E., Functional analysis of genetic mutations in nucleotide binding domain 2 of the human retina specific ABC transporter. Biochemistry, 2003. 42(36): p. 10683-96. 76. Biswas-Fiss, E.E., Interaction of the nucleotide binding domains and regulation of the ATPase activity of the human retina specific ABC transporter, ABCR. Biochemistry, 2006. 45(11): p. 3813-23. 77. Biswas-Fiss, E.E., et al., Retinoid binding properties of nucleotide binding domain 1 of the Stargardt disease-associated ATP binding cassette (ABC) transporter, ABCA4. J Biol Chem, 2012. 287(53): p. 44097-107. 78. Fishman, G.A., J.S. Farbman, and K.R. Alexander, Delayed rod dark adaptation in patients with Stargardt's disease. Ophthalmology, 1991. 98(6): p. 957-62. 79. Mata, N.L., et al., Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration. Invest Ophthalmol Vis Sci, 2001. 42(8): p. 1685-90. 80. Boyer, N.P., et al., Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem, 2012. 287(26): p. 22276-86. 81. Adler, L.t., et al., The 11-cis Retinal Origins of Lipofuscin in the Retina. Prog Mol 125 Biol Transl Sci, 2015. 134: p. e1-12. 82. Quazi, F. and R.S. Molday, ATP-binding cassette transporter ABCA4 and chemical isomerization protect photoreceptor cells from the toxic accumulation of excess 11-cis-retinal. Proc Natl Acad Sci U S A, 2014. 111(13): p. 5024-9. 83. Radu, R.A., et al., Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci, 2008. 49(9): p. 3821-9. 84. Wu, L., T. Nagasaki, and J.R. Sparrow, Photoreceptor cell degeneration in Abcr (-/-) mice. Adv Exp Med Biol, 2010. 664: p. 533-9. 85. Zhang, N., et al., Protein misfolding and the pathogenesis of ABCA4-associated retinal degenerations. Hum Mol Genet, 2015. 24(11): p. 3220-37. 86. Pandey, A., et al., Current strategies for protein production and purification enabling membrane protein structural biology. Biochem Cell Biol, 2016. 94(6): p. 507-527. 87. Choy, B.C., et al., A 10-year meta-analysis of membrane protein structural biology: Detergents, membrane mimetics, and structure determination techniques. Biochim Biophys Acta Biomembr, 2021. 1863(3): p. 183533. 88. Lee, Y.C., et al., Impact of Detergents on Membrane Protein Complex Isolation. J Proteome Res, 2018. 17(1): p. 348-358. 89. Hardy, D., et al., The yin and yang of solubilization and stabilization for wild-type and full-length membrane protein. Methods, 2018. 147: p. 118-125. 90. Xu, T., L.L. Molday, and R.S. Molday, Retinal-phospholipid Schiff-base conjugates and their interaction with ABCA4, the ABC transporter associated with Stargardt disease. J Biol Chem, 2023. 299(5): p. 104614. 91. Orwick-Rydmark, M., T. Arnold, and D. Linke, The Use of Detergents to Purify Membrane Proteins. Curr Protoc Protein Sci, 2016. 84: p. 4.8.1-4.8.35. 92. Ritchie, T.K., et al., Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Methods Enzymol, 2009. 464: p. 211-31. 93. White, S.H., The progress of membrane protein structure determination. Protein Sci, 2004. 13(7): p. 1948-9. 94. Srivatsav, A.T. and S. Kapoor, The Emerging World of Membrane Vesicles: Functional Relevance, Theranostic Avenues and Tools for Investigating Membrane Function. Front Mol Biosci, 2021. 8: p. 640355. 95. Shendge, A.A. and J.S. D'Souza, Strategic optimization of conditions for the solubilization of GST-tagged amphipathic helix-containing ciliary proteins overexpressed as inclusion bodies in E. coli. Microb Cell Fact, 2022. 21(1): p. 258. 96. Hu, J., et al., A systematic assessment of mature MBP in membrane protein production: overexpression, membrane targeting and purification. Protein Expr Purif, 2011. 80(1): p. 34-40. 97. Butt, T.R., et al., SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif, 2005. 43(1): p. 1-9. 98. Raran-Kurussi, S., et al., Removal of Affinity Tags with TEV Protease. Methods Mol Biol, 2017. 1586: p. 221-230. 126 99. Arnau, J., et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr Purif, 2006. 48(1): p. 1-13. 100. Mizrachi, D., et al., Making water-soluble integral membrane proteins in vivo using an amphipathic protein fusion strategy. Nat Commun, 2015. 6: p. 6826. 101. Yao, X., X. Fan, and N. Yan, Cryo-EM analysis of a membrane protein embedded in the liposome. Proc Natl Acad Sci U S A, 2020. 117(31): p. 18497-18503. 102. Goldie, K.N., et al., Cryo-electron microscopy of membrane proteins. Methods Mol Biol, 2014. 1117: p. 325-41. 103. Benjin, X. and L. Ling, Developments, applications, and prospects of cryo- electron microscopy. Protein Sci, 2020. 29(4): p. 872-882. 104. Kampjut, D., J. Steiner, and L.A. Sazanov, Cryo-EM grid optimization for membrane proteins. iScience, 2021. 24(3): p. 102139. 105. Rees, D.C., L. DeAntonio, and D. Eisenberg, Hydrophobic organization of membrane proteins. Science, 1989. 245(4917): p. 510-3. 106. Popot, J.L. and D.M. Engelman, Helical membrane protein folding, stability, and evolution. Annu Rev Biochem, 2000. 69: p. 881-922. 107. Qing, R., et al., Protein Design: From the Aspect of Water Solubility and Stability. Chem Rev, 2022. 122(18): p. 14085-14179. 108. Fujii, J., et al., Characterization of structural unit of phospholamban by amino acid sequencing and electrophoretic analysis. Biochem Biophys Res Commun, 1986. 138(3): p. 1044-50. 109. Fujii, J., et al., Complete complementary DNA-derived amino acid sequence of canine cardiac phospholamban. J Clin Invest, 1987. 79(1): p. 301-4. 110. Arkin, I.T., et al., Structural organization of the pentameric transmembrane alpha-helices of phospholamban, a cardiac ion channel. Embo j, 1994. 13(20): p. 4757-64. 111. Simmerman, H.K., et al., A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure. J Biol Chem, 1996. 271(10): p. 5941-6. 112. Kimura, Y., et al., Phospholamban inhibitory function is activated by depolymerization. J Biol Chem, 1997. 272(24): p. 15061-4. 113. Frank, S., et al., Toward a high-resolution structure of phospholamban: design of soluble transmembrane domain mutants. Biochemistry, 2000. 39(23): p. 6825-31. 114. Li, H., et al., Conversion of phospholamban into a soluble pentameric helical bundle. Biochemistry, 2001. 40(22): p. 6636-45. 115. Slovic, A.M., et al., Computational design of a water-soluble analog of phospholamban. Protein Sci, 2003. 12(2): p. 337-48. 116. Slovic, A.M., et al., Computational design of water-soluble analogues of the potassium channel KcsA. Proc Natl Acad Sci U S A, 2004. 101(7): p. 1828-33. 117. Cui, T., et al., NMR structure and dynamics of a designed water-soluble transmembrane domain of nicotinic acetylcholine receptor. Biochim Biophys Acta, 2012. 1818(3): p. 617-26. 118. Perez-Aguilar, J.M., et al., A computationally designed water-soluble variant of a G-protein-coupled receptor: the human mu opioid receptor. PLoS One, 2013. 127 8(6): p. e66009. 119. Zhang, S., et al., QTY code enables design of detergent-free chemokine receptors that retain ligand-binding activities. Proc Natl Acad Sci U S A, 2018. 115(37): p. E8652-E8659. 120. Qing, R., et al., QTY code designed thermostable and water-soluble chimeric chemokine receptors with tunable ligand affinity. Proc Natl Acad Sci U S A, 2019. 116(51): p. 25668-25676. 121. Tegler, L., et al., The G protein coupled receptor CXCR4 designed by the QTY code becomes more hydrophilic and retains cell signaling activity. Sci Rep, 2020. 10(1): p. 21371. 122. Hao, S., et al., QTY Code-designed Water-soluble Fc-fusion Cytokine Receptors Bind to their Respective Ligands. QRB Discov, 2020. 1: p. e4. 123. Jeppe Hallgren, K.D.T., Mads D. Pedersen, José Juan Almagro Armenteros, Paolo Marcatili, Henrik Nielsen, Anders Krogh and Ole Winther. DeepTMHMM predicts alpha and beta transmembrane proteins using deep neural networks. 2022. 124. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res, 2023. 51(D1): p. D523-d531. 125. Kelley, L.A., et al., The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc, 2015. 10(6): p. 845-58. 126. Schrodinger, LLC, The JyMOL Molecular Graphics Development Component, Version 1.8. 2015. 127. Schrodinger, LLC, The AxPyMOL Molecular Graphics Plugin for Microsoft PowerPoint, Version 1.8. 2015. 128. Molday, R.S. and K. Zhang, Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration. Prog Lipid Res, 2010. 49(4): p. 476-92. 129. Quazi, F., S. Lenevich, and R.S. Molday, ABCA4 is an N-retinylidene- phosphatidylethanolamine and phosphatidylethanolamine importer . Nat Commun, 2012. 3: p. 925. 130. Lee, J.Y., et al., Crystal structure of the human sterol transporter ABCG5/ABCG8. Nature, 2016. 533(7604): p. 561-4. 131. Rivera, A., et al., A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am J Hum Genet, 2000. 67(4): p. 800-13. 132. Nieuwkoop, T., N.J. Claassens, and J. van der Oost, Improved protein production and codon optimization analyses in Escherichia coli by bicistronic design. Microb Biotechnol, 2019. 12(1): p. 173-179. 133. Alexaki, A., et al., Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Sci Rep, 2019. 9(1): p. 15449. 134. Zhou, M., et al., Nonoptimal codon usage influences protein structure in intrinsically disordered regions. Mol Microbiol, 2015. 97(5): p. 974-87. 135. Patel, M.J., Characterization of the Functional Roles of ABCA4 in the Pathology 128 of Inherited Visual Disease. 2021, University of Delaware: United States -- Delaware. p. 172. 136. Wu, Y., et al., A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. Mol Ther Methods Clin Dev, 2018. 10: p. 38-47. 137. Jiang, F., et al., Screening of ABCA4 Gene in a Chinese Cohort With Stargardt Disease or Cone-Rod Dystrophy With a Report on 85 Novel Mutations. Invest Ophthalmol Vis Sci, 2016. 57(1): p. 145-52. 138. Jiang, Y., et al., An extensive analysis on the global codon usage pattern of baculoviruses. Arch Virol, 2008. 153(12): p. 2273-82. 139. Jumper, J., et al., Highly accurate protein structure prediction with AlphaFold. Nature, 2021. 596(7873): p. 583-589. 140. Evans, R., et al., Protein complex prediction with AlphaFold-Multimer. bioRxiv, 2022: p. 2021.10.04.463034. 141. Lee, W., et al., Genotypic spectrum and phenotype correlations of ABCA4- associated disease in patients of south Asian descent. Eur J Hum Genet, 2017. 25(6): p. 735-743. 142. Zhong, M. and R.S. Molday, Binding of retinoids to ABCA4, the photoreceptor ABC transporter associated with Stargardt macular degeneration. Methods Mol Biol, 2010. 652: p. 163-76. 143. Sun, H., P.M. Smallwood, and J. Nathans, Biochemical defects in ABCR protein variants associated with human retinopathies. Nat Genet, 2000. 26(2): p. 242-6. 144. Tanna, P., et al., Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol, 2017. 101(1): p. 25-30. 145. Patel, M.J., S.B. Biswas, and E.E. Biswas-Fiss, Functional significance of the conserved C-Terminal VFVNFA motif in the retina-specific ABC transporter, ABCA4, and its role in inherited visual disease. Biochem Biophys Res Commun, 2019. 519(1): p. 46-52.